-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Verve Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2019 to Q1 2025.
- Verve Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending March 31, 2025 was $5.68M, a 30.8% decline year-over-year.
- Verve Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending March 31, 2025 was $27.8M, a 9.92% increase year-over-year.
- Verve Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $30.3M, a 29.9% increase from 2023.
- Verve Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $23.3M, a 179% increase from 2022.
- Verve Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $8.35M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)